Intuitive Surgical, Inc. (NASDAQ:ISRG) Holdings Raised by Marco Investment Management LLC

Marco Investment Management LLC boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 61.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,227 shares of the medical equipment provider’s stock after buying an additional 1,231 shares during the quarter. Marco Investment Management LLC’s holdings in Intuitive Surgical were worth $1,598,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Picton Mahoney Asset Management lifted its position in Intuitive Surgical by 18.3% in the 1st quarter. Picton Mahoney Asset Management now owns 54,218 shares of the medical equipment provider’s stock worth $26,852,000 after buying an additional 8,393 shares in the last quarter. Foundations Investment Advisors LLC lifted its position in Intuitive Surgical by 3,012.3% in the 1st quarter. Foundations Investment Advisors LLC now owns 36,103 shares of the medical equipment provider’s stock worth $17,881,000 after buying an additional 34,943 shares in the last quarter. Baldwin Investment Management LLC lifted its position in Intuitive Surgical by 3.3% in the 1st quarter. Baldwin Investment Management LLC now owns 9,976 shares of the medical equipment provider’s stock worth $4,941,000 after buying an additional 319 shares in the last quarter. Prosperity Consulting Group LLC lifted its position in Intuitive Surgical by 5.7% in the 1st quarter. Prosperity Consulting Group LLC now owns 2,050 shares of the medical equipment provider’s stock worth $1,015,000 after buying an additional 111 shares in the last quarter. Finally, Galvin Gaustad & Stein LLC lifted its position in Intuitive Surgical by 144.4% in the 1st quarter. Galvin Gaustad & Stein LLC now owns 1,019 shares of the medical equipment provider’s stock worth $505,000 after buying an additional 602 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

NASDAQ:ISRG opened at $493.95 on Tuesday. The firm’s 50-day moving average is $528.51 and its 200-day moving average is $534.63. Intuitive Surgical, Inc. has a 52-week low of $425.00 and a 52-week high of $616.00. The company has a market cap of $177.07 billion, a price-to-earnings ratio of 68.89, a PEG ratio of 5.20 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same quarter in the previous year, the firm posted $1.78 EPS. The business’s revenue was up 21.4% compared to the same quarter last year. Equities analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of Intuitive Surgical stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the sale, the executive vice president directly owned 353 shares in the company, valued at approximately $173,845.44. The trade was a 92.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mark Brosius sold 216 shares of Intuitive Surgical stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the sale, the senior vice president owned 907 shares in the company, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,610 shares of company stock worth $3,858,340. 0.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Truist Financial increased their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a “hold” rating to a “sell” rating and cut their price target for the company from $515.00 to $440.00 in a report on Monday, June 9th. Piper Sandler restated an “overweight” rating and set a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Robert W. Baird cut their price target on shares of Intuitive Surgical from $600.00 to $575.00 and set an “outperform” rating on the stock in a report on Wednesday, April 23rd. Finally, Citigroup restated a “buy” rating and set a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $592.05.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.